HCP Connect Contributor
Dr. Simran Kohli
Dr. Simran Kohli contributes infectious diseases drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.
Recent Drug Updates
14 total
Infectious Disease
COVID-19 Treatment Options: Comparing Ensitrelvir, Paxlovid, and Lagevrio
COVID-19 treatment options: ensitrelvir, Paxlovid, and Lagevrio compared for efficacy and guidelines in 2026.
Infectious Disease
CDC Updates Hepatitis B Vaccination Guidelines: Universal Vaccination for Adults 19-59 and Catch-Up for Those Over 60
CDC updates hepatitis B vaccination guidelines: universal vaccination for adults 19-59 and catch-up for those over 60.
Infectious Disease
FDA Approves Doravirine and Islatravir for HIV-1: Once Daily Two-Drug Regimen
FDA approves doravirine and islatravir for HIV-1: a once-daily two-drug regimen improving adherence.
Infectious Disease
FDA Expands Arexvy Indication for RSV: Now Approved for Immunocompromised Adults Aged 18 to 49
FDA expands Arexvy indication for RSV: now approved for immunocompromised adults aged 18 to 49, enhancing prevention efforts.
Infectious Disease
CDC Updates RSV Vaccine Guidelines: Arexvy Recommended for High-Risk Adults 18-49
CDC updates RSV vaccine guidelines: Arexvy recommended for high-risk adults 18-49, enhancing prevention strategies.
Infectious Disease
CDC Updates Long COVID Management Guidelines: Focus on Patient-Centered Care
CDC updates Long COVID guidelines focusing on patient-centered care and symptom management strategies for primary care providers.
Infectious Disease
FDA Reviews Ensitrelvir for COVID-19 Post-Exposure Prevention: First Oral Antiviral in 2026
FDA reviews ensitrelvir for COVID-19 post-exposure prevention: first oral antiviral expected in 2026.
Infectious Disease
FDA Authorizes Nirmatrelvir-Ritonavir (Paxlovid) for COVID-19: 89% Hospitalization Reduction in EPIC-HR Trial
FDA authorizes nirmatrelvir-ritonavir (Paxlovid) for COVID-19: 89% hospitalization reduction in high-risk adults.
Infectious Disease
WHO's 2026 Guidelines: A Comprehensive Approach to Combatting Antimicrobial Resistance
Explore WHO's 2026 guidelines on antimicrobial resistance, focusing on surveillance, infection control, and research investment.
Medical Research
Improve Ovarian Cancer Detection with Personalized Risk Score
Enhance patient outcomes with a cost-effective tool that combines blood test results and age for accurate ovarian cancer detection in women over 50.
Digital Health
Automate 90% of Intake Workflows with AI
Discover how AI-powered automation can streamline post-acute care workflows, freeing staff to focus on patient care and reducing administrative burdens.
Medical Research
Plant-Based Diet Cuts Type 2 Diabetes Risk
Discover how a plant-based diet can lower type 2 diabetes risk while reducing greenhouse gas emissions, benefiting both human and planetary health.
Digital Health
Stay Ahead with Daily Digital Health Updates
Get the latest digital health news, trends, and insights to enhance patient care and stay informed about industry developments and innovations.
Medical Research
Reuse Patient Studies to Cut Drug Dev Costs
Discover how reusing existing patient preference studies can optimize resource allocation and streamline drug development processes, reducing costs and improving efficiency.